Using EGFR Antibodies as a First Line Therapy Depending on Tumor Sidedness

Using EGFR Antibodies as a First Line Therapy Depending on Tumor Sidedness

User Photo
obr

2 years
73 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The choice of first line therapy differs on tumor sidedness. Professor Alan P. Venook, MD, joins us from the 2018 Gastrointestinal Cancers Symposium and talks about the deciding factor when it comes to the first line of therapy for either left-sided or right-sided patients.
Up Next Autoplay